Reata Stock Holders Approved the Firm’s Merger with Biogen

Reat Pharmaceuticals Merger with Biogen
Reata Pharmaceuticals announced that at a special meeting held today, preliminary results indicate that the stockholders of the firm have voted to approve the Company’s previously announced acquisition (the “Merger”) by Biogen (BIIB).

Around 99.65% of the votes cast by the Company’s Class A common stockholders and Class B common stockholders, voting as . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.